NCT00488449已完成1 期
A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation Study in Healthy Adult Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing
研究概览
简要总结
The purpose of this study is to compare the effects of single and repeat doses of GSK256073 with placebo in HVT subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Adult males or females between 18 and 55 years of age, inclusive.
- •Female subjects must be of non-childbearing potential
- •Body weight > 50 kg (110 pounds) and body mass index (BMI) 19 and 31 where:
- •Subjects with QTc < 450 msec at screening (or QTc < 480 msec for subjects with Bundle Branch Block).
- •A signed and dated written informed consent prior to admission to the study.
- •The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restriction
排除标准
- •Systolic blood pressure < 100 mmHg or 150 mmHg and/or diastolic blood pressure = 100 mmHg at screening.
- •History of significant cardiac arrhythmias
- •Active peptic ulcer disease (PUD) and/or history of PUD within 1 year.
- •A serum uric acid concentration 8mg/dL
- •Screening test positive for H. Pylori using the non-radioactive breath test
- •History of gout and/or hyperuricemia
- •History of Gilbert's syndrome
- •A serum creatinine concentration above the normal reference range
- •History of kidney stones
- •PT and/or aPTT above the reference range
- •History of recurrent indigestion, stomach upset or diarrhea
- •Liver function tests (LFTs) or creatinine phosphokinase (CPK) 1.5X ULN
- •Screening stool test positive for occult blood
- •Screening peripheral blood smear with abnormal RBCs
- •CBC, MCV, and/or reticulocyte count corrected for haemoglobin level above the reference range at screening
- •Reduced G6PD activity
- •Serum haptoglobin outside the reference range at screening
- •Total serum LDH > 1.25% above the ULN at screening
- •Positive HIV, Hepatitis B or Hepatitis C at screening
- •The subject has a positive pre-study urine drug/ serum alcohol screen.
- •History of alcohol consumption exceeding, on average, 7 drinks/week for women or 14 drinks/week for men within 6 months of the first dose of study medication or a positive alcohol test at screening
- •History of use of tobacco or nicotine containing products within 6 months of screening or a positive urine cotinine screen
- •Use of prescription (including hormone replacement therapy) or non-prescription drugs and vitamins within 7 days or 5 half-lives prior to administration of study medication. An exception is acetaminophen which is allowed at doses of 2g/day.
- •Use of dietary/herbal supplements within 14 days prior to treatment with study medication
- •Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to dosing.
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
- •Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.
- •Unwillingness of male subjects to use a condom/spermicide
- •Pregnant or nursing women.
- •History of flushing (>1 episode annually).
- •Fasting blood glucose 110 mg/dl and/or history of type I or type II DM
- •History of intra-ocular pathology
- •History of recurrent gum bleeding
- •History of bleeding haemorrhoids
结局指标
主要结局
AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing
时间窗: throughout the study (Parts A &B)
Measures of accumulation ratios
时间窗: throughout the study (Ro, Rp, and Rs)[Part B]
AUC and Cmax
时间窗: throughout the study (Part A & B)
次要结局
- LDL, HDL, ApoA1, ApoA2, Apo B and Lp(a)(on Days 1, 14, and 15.)
- Tmax, t½, Ae, and CLr (Parts A & B) Cmax, ss, Ct, t½, Ae, CLr, and accumulation ratios (Part B)(throughout the study)
- PD response: NEFA and TG (6 and 24 hours post- dose)((6 and 24 hours post- dose))
- Levels of GSK256073 to derive pharmacokinetic parameters following repeat dose administration.
- Lipid levels(on Days 1, 14, and 15)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Second Study to Determine the Effect of GSK256073A on HVTsHealthy SubjectsDyslipidaemiasNCT00551694GlaxoSmithKline4
撤回
2 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)Autoimmune DiseasesNCT03239600GlaxoSmithKline
已完成
2 期
Safety Escalating Repeat IV, in Stroke PatientsIschaemic Attack, TransientNCT00833989GlaxoSmithKline42
已完成
2 期
Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular DystrophyMuscular DystrophiesNCT01153932GlaxoSmithKline53
已完成
1 期
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.HIV InfectionInfection, Human Immunodeficiency VirusNCT00386347GlaxoSmithKline56